-
1.发明授权Compositions and methods for drug-sensitization or inhibition of a cancer cell 有权用于药物敏化或抑制癌细胞的组合物和方法公开(公告)号：US09134329B2
公开(公告)日：2015-09-15
申请号：US14322727
申请日：2014-07-02
申请人： James Sacchettini , Niam Zhou , Dwight Baker , Steven A. Maxwell , Deeann Wallis
发明人： James Sacchettini , Niam Zhou , Dwight Baker , Steven A. Maxwell , Deeann Wallis
IPC分类号： A61K31/00 , A61K31/35 , A61K31/7034 , G01N33/84 , A61K45/06 , A61K31/395 , A61K31/435 , A61K31/122 , A61K31/136 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/5377 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K38/08 , C07D498/22 , G01N33/58
CPC分类号： A61K31/395 , A61K31/122 , A61K31/136 , A61K31/337 , A61K31/435 , A61K31/4745 , A61K31/475 , A61K31/5377 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K38/08 , A61K45/06 , C07D498/22 , G01N33/582 , G01N33/84 , G01N2800/52 , A61K2300/00
摘要： The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
摘要翻译： 本公开提供了利福霉素和利福霉素衍生物组合物，其包括能够在癌细胞中引起药物敏化或抑制癌细胞的利福布丁和利福布汀衍生物组合物。 本公开还提供了将这种组合物施用于癌细胞以使其对药物（例如化学治疗剂）敏化或直接抑制它们的方法。 本公开还提供了施用这样的组合物以增加癌细胞中的活性氧（ROS），特别是超氧化物的方法。 本公开进一步提供了确定癌症是否将响应化学治疗剂以及是否施用基于患者的癌细胞中的ROS水平的利福霉素或利福霉素衍生物的方法。
-
2.发明申请COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL 有权用于药物敏感性或抑制癌症细胞的组合物和方法公开(公告)号：US20140314878A1
公开(公告)日：2014-10-23
申请号：US14322727
申请日：2014-07-02
申请人： James Sacchettini , Niam Zhou , Dwight Baker , Steven A. Maxwell , Deeann Wallis
发明人： James Sacchettini , Niam Zhou , Dwight Baker , Steven A. Maxwell , Deeann Wallis
IPC分类号： C07D498/22 , A61K31/675 , A61K31/704 , A61K31/475 , A61K31/573 , A61K31/69 , A61K33/24 , A61K31/7068 , A61K31/136 , A61K31/122 , A61K38/08 , A61K31/4745 , A61K31/337 , A61K31/5377 , A61K31/435
CPC分类号： A61K31/395 , A61K31/122 , A61K31/136 , A61K31/337 , A61K31/435 , A61K31/4745 , A61K31/475 , A61K31/5377 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K38/08 , A61K45/06 , C07D498/22 , G01N33/582 , G01N33/84 , G01N2800/52 , A61K2300/00
摘要： The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
摘要翻译： 本公开提供了利福霉素和利福霉素衍生物组合物，其包括能够在癌细胞中引起药物敏化或抑制癌细胞的利福布丁和利福布汀衍生物组合物。 本公开还提供了将这种组合物施用于癌细胞以使其对药物（例如化学治疗剂）敏化或直接抑制它们的方法。 本公开还提供了施用这样的组合物以增加癌细胞中的活性氧（ROS），特别是超氧化物的方法。 本公开进一步提供了确定癌症是否将响应化学治疗剂以及是否施用基于患者的癌细胞中的ROS水平的利福霉素或利福霉素衍生物的方法。
-
公开(公告)号：US20160354358A1
公开(公告)日：2016-12-08
申请号：US15240270
申请日：2016-08-18
IPC分类号： A61K31/454 , A61K31/427 , A61K31/7048 , A61K47/48 , A61K31/5377
CPC分类号： A61K31/454 , A61K31/427 , A61K31/435 , A61K31/5377 , A61K31/7048 , A61K45/06 , A61K47/542 , A61K47/545 , Y02A50/411 , Y02A50/414 , Y02A50/419 , Y02A50/421 , Y02A50/423 , Y02A50/49 , Y02A50/491 , A61K2300/00
摘要： Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
摘要翻译： 提供了用于抑制和/或使寄生虫对抗寄生虫药敏感或再致敏的组合物和方法。 组合物可以包含足以抑制或诱导寄生虫药物敏化的量和制剂的利福霉素衍生物或其药学上可接受的盐，水合物或前药。 所述方法可以包括给予寄生虫的利福霉素衍生物或其药学上可接受的盐，水合物或前药，其量和制剂足以抑制或诱导寄生虫中的药物敏化。
-
4.发明申请COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL 审中-公开用于药物敏感性或抑制癌症细胞的组合物和方法公开(公告)号：US20150017673A1
公开(公告)日：2015-01-15
申请号：US14013842
申请日：2013-08-29
申请人： James Sacchettini , Nian Zhou , Dwight Baker , Steven A. Maxwell , Deeann Wallis
发明人： James Sacchettini , Nian Zhou , Dwight Baker , Steven A. Maxwell , Deeann Wallis
IPC分类号： G01N33/84 , G01N33/58 , A61K31/435
CPC分类号： A61K31/395 , A61K31/122 , A61K31/136 , A61K31/337 , A61K31/435 , A61K31/4745 , A61K31/475 , A61K31/5377 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K38/08 , A61K45/06 , C07D498/22 , G01N33/582 , G01N33/84 , G01N2800/52 , A61K2300/00
摘要： The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
摘要翻译： 本公开提供了利福霉素和利福霉素衍生物组合物，其包括能够在癌细胞中引起药物敏化或抑制癌细胞的利福布丁和利福布汀衍生物组合物。 本公开还提供了将这种组合物施用于癌细胞以使其对药物（例如化学治疗剂）敏化或直接抑制它们的方法。 本公开还提供了施用这样的组合物以增加癌细胞中的活性氧（ROS），特别是超氧化物的方法。 本公开进一步提供了确定癌症是否将响应化学治疗剂以及是否施用基于患者的癌细胞中的ROS水平的利福霉素或利福霉素衍生物的方法。
-
公开(公告)号：US10226455B2
公开(公告)日：2019-03-12
申请号：US15240270
申请日：2016-08-18
IPC分类号： A61K31/454 , A61K31/7048 , A61K31/427 , A61K31/435 , A61K31/5377 , A61K47/54 , A61K45/06
摘要： Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
